On 29 September 2026, the HTA Council completed the evidence appraisal of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) [100 mcg/62.5 mcg/25 mcg per pre-dispensed dose, dry powder inhalation (DPI)] and budesonide/glycopyrronium/formoterol fumarate (BUD/GLY/FORM) [160 mcg/7.2 mcg/4.8 mcg per actuation, pressurized metered-dose inhaler (MDI)] for the initial maintenance treatment and follow-up maintenance treatment of patients with chronic obstructive pulmonary continue reading : HTA Council Preliminary Recommendation on fluticasone furoate/umeclidinium/vilanterol [100 mcg/62.5 mcg/25 mcg per pre-dispensed dose, dry powder for inhalation] and budesonide/glycopyrronium/formoterol fumarate [160 mcg/7.2 mcg/4.8 mcg per actuation, pressurized metered-dose inhaler] for the treatment of patients with chronic obstructive pulmonary disease